JP2022551219A - レンチウイルスベクターの製造方法および構築物 - Google Patents

レンチウイルスベクターの製造方法および構築物 Download PDF

Info

Publication number
JP2022551219A
JP2022551219A JP2022508573A JP2022508573A JP2022551219A JP 2022551219 A JP2022551219 A JP 2022551219A JP 2022508573 A JP2022508573 A JP 2022508573A JP 2022508573 A JP2022508573 A JP 2022508573A JP 2022551219 A JP2022551219 A JP 2022551219A
Authority
JP
Japan
Prior art keywords
gene
lentiviral
promoter
vector
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022508573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551219A5 (https=
Inventor
ヤン シン，
アナンディタ セス，
ビンナン グ，
Original Assignee
ロンザ ウォーカーズヴィル，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロンザ ウォーカーズヴィル，インコーポレーテッド filed Critical ロンザ ウォーカーズヴィル，インコーポレーテッド
Publication of JP2022551219A publication Critical patent/JP2022551219A/ja
Publication of JP2022551219A5 publication Critical patent/JP2022551219A5/ja
Priority to JP2025092432A priority Critical patent/JP2025148329A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C12N15/8673—Special methods for packaging systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C12N15/8676—Special methods for targeting systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022508573A 2019-08-23 2020-08-24 レンチウイルスベクターの製造方法および構築物 Pending JP2022551219A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025092432A JP2025148329A (ja) 2019-08-23 2025-06-03 レンチウイルスベクターの製造方法および構築物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962890904P 2019-08-23 2019-08-23
US62/890,904 2019-08-23
PCT/US2020/047650 WO2021041322A1 (en) 2019-08-23 2020-08-24 Methods and constructs for production of lentiviral vector

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025092432A Division JP2025148329A (ja) 2019-08-23 2025-06-03 レンチウイルスベクターの製造方法および構築物

Publications (2)

Publication Number Publication Date
JP2022551219A true JP2022551219A (ja) 2022-12-08
JP2022551219A5 JP2022551219A5 (https=) 2023-08-31

Family

ID=74679320

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022508573A Pending JP2022551219A (ja) 2019-08-23 2020-08-24 レンチウイルスベクターの製造方法および構築物
JP2025092432A Pending JP2025148329A (ja) 2019-08-23 2025-06-03 レンチウイルスベクターの製造方法および構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025092432A Pending JP2025148329A (ja) 2019-08-23 2025-06-03 レンチウイルスベクターの製造方法および構築物

Country Status (7)

Country Link
US (3) US12037599B2 (https=)
EP (1) EP4017987A4 (https=)
JP (2) JP2022551219A (https=)
KR (1) KR20220047635A (https=)
CN (1) CN114286864B (https=)
IL (1) IL290820A (https=)
WO (1) WO2021041322A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192193A1 (en) * 2021-03-09 2022-09-15 The Board Of Regents Of The University Of Texas System Methods and compositions for mutagenesis screening in mammalian cells
CN117529491A (zh) * 2021-04-23 2024-02-06 阿西莫夫公司 用于慢病毒载体产生的稳定产生系统
WO2023083760A1 (en) 2021-11-09 2023-05-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Koala retrovirus envelope glycoproteins and uses thereof
KR20260013198A (ko) * 2023-05-12 2026-01-27 론자 바이올로직스 피엘씨 고수율 생성물 생산을 위한 트랜스포사제를 이용한 하이브리드 일시적 형질감염

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017089308A1 (en) * 2015-11-24 2017-06-01 Glaxosmithkline Intellectual Property Development Limited Stable cell lines for retroviral production
WO2017144892A1 (en) * 2016-02-26 2017-08-31 Ucl Business Plc Nucleic acid constructs for producing retroviral vectors
WO2017144893A1 (en) * 2016-02-26 2017-08-31 Ucl Business Plc Retrovirus packaging cell

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262049B2 (en) * 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
US10087463B2 (en) 2000-10-31 2018-10-02 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
ATE437221T1 (de) 2001-05-14 2009-08-15 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
US20090042297A1 (en) * 2007-06-01 2009-02-12 George Jr Alfred L Piggybac transposon-based vectors and methods of nucleic acid integration
DK2307551T3 (en) 2008-06-18 2017-03-20 Oxford Biomedica (Uk) Ltd CLEANING RETROVIRAL VECTORS
WO2011097447A2 (en) 2010-02-04 2011-08-11 Neurologix, Inc. Production of recombinant virus
SI2480678T1 (sl) 2010-09-02 2014-06-30 Molmed Spa Stabilno proizvajanje lentivirusnih vektorjev
CA3108569A1 (en) 2010-10-05 2012-04-12 Bayer Cropscience Lp A system and method of establishing an agricultural pedigree for at least one agricultural product
US20140315294A1 (en) 2011-11-24 2014-10-23 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
WO2013090409A1 (en) 2011-12-12 2013-06-20 The Children's Hospital Of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
EP2970920B1 (en) 2013-03-15 2018-04-25 The Children's Hospital of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
FR3010720B1 (fr) 2013-09-16 2017-08-11 Genethon Procede de production de virus enveloppes
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
GB201417042D0 (en) 2014-09-29 2014-11-12 Fkd Therapies Oy Method
US20160267432A1 (en) 2015-03-13 2016-09-15 GeoPRI, LLC Systems and methods for tracking an individual unit
US20160350715A1 (en) 2015-05-29 2016-12-01 Eugenio Minvielle Nutrition Based Food System and Method
US10699284B2 (en) 2016-08-10 2020-06-30 Label Insight, Inc. Information management system for product ingredients to fill gaps in the market and to determine proper attribution
GB201705927D0 (en) 2017-04-12 2017-05-24 Oxford Genetics Ltd Vector
GB201715052D0 (en) 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
EP3456822A1 (en) 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Inducible aav rep genes
KR20210108406A (ko) 2018-12-21 2021-09-02 론자 워커스빌 아이엔씨. 바이러스 벡터의 자동화된 생산

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017089308A1 (en) * 2015-11-24 2017-06-01 Glaxosmithkline Intellectual Property Development Limited Stable cell lines for retroviral production
WO2017144892A1 (en) * 2016-02-26 2017-08-31 Ucl Business Plc Nucleic acid constructs for producing retroviral vectors
WO2017144893A1 (en) * 2016-02-26 2017-08-31 Ucl Business Plc Retrovirus packaging cell

Also Published As

Publication number Publication date
IL290820A (en) 2022-04-01
US20240336936A1 (en) 2024-10-10
WO2021041322A1 (en) 2021-03-04
US12037599B2 (en) 2024-07-16
CN114286864B (zh) 2025-08-15
EP4017987A4 (en) 2023-10-04
CN114286864A (zh) 2022-04-05
EP4017987A1 (en) 2022-06-29
US20250263749A1 (en) 2025-08-21
US20210062220A1 (en) 2021-03-04
JP2025148329A (ja) 2025-10-07
KR20220047635A (ko) 2022-04-18
US12391960B2 (en) 2025-08-19

Similar Documents

Publication Publication Date Title
US12391960B2 (en) Methods and constructs for production of lentiviral vector
JP7469280B2 (ja) レンチウイルスベクターのバイオ生産法
Chen et al. Rapid lentiviral vector producer cell line generation using a single DNA construct
AU2019241301B2 (en) Method for large-scale production of lentivirus by using GMP-level serum-free suspension cells
US12398404B2 (en) Methods and constructs for transient production of lentiviral vector
HK40063602B (zh) 慢病毒载体产生方法及构建体
HK40063602A (en) Methods and constructs for production of lentiviral vector
CN111254161A (zh) 一种建立基于crispr的基因敲减肺癌细胞株的方法及细胞株
HK40069471A (en) Methods and constructs for transient production of lentiviral vector
Accordino Lentiviral Vector Production at High Cell Density by Transient Transfection of Suspended Culture HEK Cells
US20230279388A1 (en) Replication Competent Virus Assay
HK40042109A (en) Method for large-scale production of lentivirus by using gmp-level serum-free suspension cells
CN116218880A (zh) 一种提高病毒滴度的重组载体及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220210

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20220209

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603